
In this phase 2b study, 190 patients were treated with varying doses or placebo. Those continuing 300 mg showed sustained improvements in EULAR scores and symptom assessments. Salivary flow and autoantibody levels also improved. Safety was consistent, with few serious adverse events and only isolated neutropenia cases post-treatment, supporting ianalumab’s long-term safety and efficacy profile.
Like
Save
Share